The European Medicines Agency (EMA) said its safety committee concluded that a warning about unusual blood clots with low blood platelets should be added to the vaccine's labels.
The EMA found that all instances had occurred in adults under 60 years, mostly women, within three weeks of vaccination, adding that all available evidence, including eight reports of cases in the United States, were part of its assessment.
"In the absence of an alternative cause for the clinical syndrome, VSIG believed that a causative link to vaccination should be assumed at this time," the TGA said.
The TGA said her case had been complicated by underlying medical conditions, including diabetes, "as well as some atypical features."
The decision, which would remove the shot from Denmark's vaccination scheme, could delay the country's vaccine rollout by up to four weeks, based on previous statements by health bodies.
A spate of countries across the world, including France and Germany, have resumed administering the shot to some age groups, mostly those above 50 or 60.
J&J said on Tuesday it would delay the rollout of its COVID-19 vaccine in Europe and was reviewing cases of extremely rare blood clots in people after they received the shot with European health authorities.
US federal health agencies on Tuesday recommended pausing the use of the vaccine as six women under 50 developed rare blood clots after receiving the shot, dealing a fresh setback to efforts to tackle the pandemic.
Nearly 5 million people in the United States had received J&J's vaccine as of Thursday morning, according to the U.S. Centers for Disease Control and Prevention.
Europe's medicines regulator said this week it found rare cases of blood clots among some adult recipients of the shot, although the vaccine's advantages still outweighed its risks.
Greece has reported 288,230 cases of COVID-19 and a total of 8,680 deaths. It has administered 378,997 doses of the AstraZeneca vaccine so far and ordered another 1.35 million doses.
Spain introduced the restriction on Wednesday after the European Medicines Agency reported a link between the shots and a rare form of brain blood clots affecting roughly one in every 100,000 people under 60 vaccinated.
As of Thursday night, only around 45% of people had confirmed their vaccine appointments for Friday, he added.
The French decision came after European drug regulators said on Wednesday there was a possible link between AstraZeneca's COVID-19 shot and a very small number of cases of rare blood clots.
"This is a logical choice and one of security," Dominique Le Guludec, the head of the HAS, told reporters.
"AstraZeneca confirmed to us not being under any obligation to other parties that would impede to complete the fulfilment of its obligations" to the EU, the Commission spokeswoman said when asked about Hancock's statements.
Under the EU contract, AstraZeneca committed to supplying vaccines produced in four European factories, two of which are in Britain: Oxford Biomedica and Cobra Biologics.
The vaccine is of great use for the elderly, among whom many fall seriously ill each day.
"At the same time, we haven't seen these rare and serious side effects among our elderly. That is the background to why we are lifting the suspension for people older than 65."
"In the morning I got a report... showing that there are more and more people willing to get vaccinated and also to get vaccinated with the AstraZeneca vaccine," Mateusz Morawiecki told reporters.
"This shows that we made the right decision not to suspend vaccinations with AstraZeneca. There are definitely more people willing to be vaccinated with this vaccine."
France was one of more than a dozen European Union states that suspended use of the Anglo-Swedish vaccine this week following reports of blood clotting in a small number of recipients of the shot.
The EU's drug watchdog (EMA) on Thursday said it was convinced the benefits of the AstraZeneca vaccine outweighed the risks.
Mexico will receive 2.5 million does of the vaccine and Canada will receive 1.5 million doses, the official said.
"This virus has no borders," the official told Reuters on condition of anonymity. "We only put the virus behind us if we're helping our global partners."
Concerns about reports of blood clots, along with low platelet levels, have led to European countries including Germany to pause the rollout of the shot while the cases are investigated.
*"The available evidence does not suggest that blood clots in veins (venous thromboembolism) are caused by COVID-19 Vaccine AstraZeneca," the MHRA said.
"As the MHRA (Britain's Medicines and Healthcare Products Regulatory Agency) has said, blood clots occur naturally but there is no evidence that they are any more likely to occur following vaccination, so as such there's no evidence of any causal link between blood clots and the AZ vaccine," he told reporters.